Nonalcoholic fatty liver disease, associated lipidomic changes, and preeclampsia risk

非酒精性脂肪肝、相关脂质组学变化和先兆子痫风险

基本信息

项目摘要

PROJECT SUMMARY Preeclampsia (PE) is a leading cause of maternal morbidity and mortality in the United States which has led to an urgent need to accurately predict its risk. It is not known how nonalcoholic fatty liver disease (NAFLD), the liver manifestation of metabolic syndrome and the most prevalent liver disease among women, contributes to PE risk. The long-term objective of this proposal is to define the relationship between NAFLD and PE, to identify strategies to reduce the risk of PE, and to improve short- and long-term maternal outcomes in this population. This project will evaluate the independent association of NAFLD with PE among overweight and obese women. It will also study relevant lipid alterations in women with NAFLD in pregnancy which are associated with endothelial dysfunction that leads to the clinical syndrome of PE, among NAFLD (compared to non-NAFLD) patients during pregnancy. The Specific Aims of this proposal are: (1) To prospectively assess whether NAFLD is an independent risk factor for: i) PE among overweight/obese women and ii) PE with liver injury; (2) To determine whether women with NAFLD in pregnancy have altered levels of bioactive lipids associated with endothelial cell dysfunction, compared with women without NAFLD in pregnancy. This study will be performed in the Mount Sinai Health System, which provides care to a diverse and multiethnic patient population disproportionately affected by both NAFLD and PE. This application will support the candidate's career development into an independent patient-oriented investigator focused on the influence of liver disease in pregnancy on preeclampsia risk and future maternal cardiovascular and liver health, a significant unmet need. The proposed career development plan integrates advanced coursework in translational epidemiology, lipidomics assessment, prospective study design/ analysis, and biostatistics, and experiential learning through the conduct of the proposed research plan, all within a highly supportive research environment. The mentorship team which includes senior investigators with expertise in epidemiologic and translational research in hepatology (Friedman and Terrault), preeclampsia (Roberts), and prospective study design and advanced biostatistical analysis (Sigel), will guide the candidate's research and career development. The superb institutional infrastructure for developing successful clinical investigators and the substantial institutional commitment to the candidate greatly strengthen this application. At the conclusion of this proposal's funding period, Dr. Kushner will be optimally positioned as an independent physician-investigator studying the intersection of liver disease and PE, and their implications on future maternal health.
项目概要 先兆子痫 (PE) 是美国孕产妇发病和死亡的主要原因 迫切需要准确预测其风险。目前尚不清楚非酒精性脂肪性肝病 (NAFLD) 是如何发生的 代谢综合征的肝脏表现和女性中最常见的肝脏疾病,有助于 私募股权风险。该提案的长期目标是定义 NAFLD 和 PE 之间的关系,以 确定降低 PE 风险并改善短期和长期孕产妇结局的策略 人口。该项目将评估超重和肥胖人群中 NAFLD 与 PE 的独立关联。 肥胖女性。它还将研究妊娠期患有 NAFLD 的女性的相关脂质变化,这些变化是 在 NAFLD 中,与导致 PE 临床综合征的内皮功能障碍相关(与 非NAFLD)怀孕期间的患者。本提案的具体目标是: (1) 前瞻性评估 NAFLD 是否是以下因素的独立危险因素:i) 超重/肥胖女性的 PE 和 ii) 肝脏 PE 受伤; (2) 确定妊娠期患有 NAFLD 的女性生物活性脂质水平是否发生改变 与妊娠期未患 NAFLD 的女性相比,与内皮细胞功能障碍相关。这项研究 将在西奈山卫生系统进行,该系统为多元化和多种族的患者提供护理 受 NAFLD 和 PE 影响的人群不成比例。该申请将支持候选人 职业发展成为一名以患者为中心的独立研究者,专注于肝病的影响 妊娠期对先兆子痫风险以及未来孕产妇心血管和肝脏健康的影响,是一个重大未得到满足的问题 需要。拟议的职业发展计划整合了转化流行病学的高级课程, 脂质组学评估、前瞻性研究设计/分析、生物统计学以及体验式学习 拟议研究计划的实施,全部在高度支持的研究环境中进行。这 导师团队包括具有流行病学和转化研究专业知识的高级研究人员 肝病学(Friedman 和 Terrault)、先兆子痫(Roberts)以及前瞻性研究设计和高级研究 生物统计分析(Sigel),将指导候选人的研究和职业发展。超棒的 培养成功临床研究者的机构基础设施和实质性机构 对候选人的承诺极大地加强了这一申请。在本提案的资助结束时 在此期间,库什纳博士将被最佳定位为一名独立的医师研究员,研究 肝病和 PE 的交叉及其对未来孕产妇健康的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tatyana Kushner其他文献

Tatyana Kushner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

抑酸类药物影响肠道微生态促进胆石形成的生物标志物研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
甲状腺癌多组学预测性生物标志物的识别及其受高碘暴露影响的研究
  • 批准号:
    82173638
  • 批准年份:
    2021
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
北极楚科奇海海冰变化及其对有机碳来源影响的生物标志物记录研究
  • 批准号:
    41976229
  • 批准年份:
    2019
  • 资助金额:
    64 万元
  • 项目类别:
    面上项目
土壤中砷形态对砷-PFOA复合污染的蚯蚓联合毒性影响及机制研究
  • 批准号:
    41907351
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目
PM2.5对儿童行为能力影响的急性效应研究
  • 批准号:
    41907368
  • 批准年份:
    2019
  • 资助金额:
    26.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Leveraging Automated Optimization of Inspired Oxygen and Oxidized Biomarker Lipidomics for Targeted Oxygenation during Mechanical Ventilation: a Pragmatic Clinical Trial
利用吸入氧和氧化生物标志物脂质组学的自动优化在机械通气期间进行靶向氧合:一项实用的临床试验
  • 批准号:
    10592000
  • 财政年份:
    2023
  • 资助金额:
    $ 19.07万
  • 项目类别:
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents with Eating Disorders
青少年饮食失调阿片类药物拮抗药效生物标志物的开发
  • 批准号:
    10662801
  • 财政年份:
    2023
  • 资助金额:
    $ 19.07万
  • 项目类别:
Effects of Resonance-Frequency Breathing on Preclinical Alzheimer’s Disease Biomarkers and Cognition
共振频率呼吸对临床前阿尔茨海默病生物标志物和认知的影响
  • 批准号:
    10591329
  • 财政年份:
    2023
  • 资助金额:
    $ 19.07万
  • 项目类别:
Metabolic Obesity Phenotypes and Obesity-related Cancer Survival
代谢性肥胖表型和肥胖相关的癌症生存
  • 批准号:
    10752062
  • 财政年份:
    2023
  • 资助金额:
    $ 19.07万
  • 项目类别:
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents with Eating Disorders
青少年饮食失调阿片类药物拮抗药效生物标志物的开发
  • 批准号:
    10662801
  • 财政年份:
    2023
  • 资助金额:
    $ 19.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了